Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Structure-based design of novel anticancer agents.

F M Uckun1, E A Sudbeck, C Mao

  • 1Drug Discovery Program, Parker Hughes Cancer Center, Parker Hughes Institute, 2665 Long Lake Road, St. Paul, Minnesota55113, USA. Fatih_Uckun@ih.org

Current Cancer Drug Targets
|August 22, 2002
PubMed
Summary

New anticancer agents targeting tubulin and protein tyrosine kinases show promise. SPIKET and COBRA compounds disrupt microtubule organization, while kinase inhibitors like WHI-P97 and LFM-A13 induce cancer cell death and enhance chemotherapy sensitivity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Interpretation for the health professional standards in appropriate range of body mass index and body weight management for the oldest old].

Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi·2026
Same author

[Association between blood selenium level and depressive symptoms in older adults aged 65 years and above in 18 longevity areas in China].

Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi·2026
Same author

[Identification and validation of plasma biomarkers for mild cognitive impairment based on mRNA N<sup>6</sup>-methyladenosine methylome analysis].

Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi·2026
Same author

[Association between physical activity and non-alcoholic fatty liver disease among adults aged 65 and above in longevity regions of China].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]·2026
Same author

Overexpression of OsLTSD2 decreases cold tolerance in rice.

Plant biology (Stuttgart, Germany)·2026
Same author

[Association between body composition and high-sensitivity C-reactive protein in older adults aged 65 years and above in 18 longevity areas in China].

Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi·2026

Area of Science:

  • Biochemistry
  • Cell Biology
  • Pharmacology

Background:

  • Novel agents targeting cytoskeletal proteins like tubulin and protein tyrosine kinases are emerging as potential anti-cancer therapies.
  • Synthetic spiroketal pyrans (SPIKET) and monotetrahydrofuran (COBRA) compounds interact with alpha- and beta-tubulin.
  • Protein tyrosine kinase inhibitors, including EGFR and JAK inhibitors, are also under investigation for cancer treatment.

Purpose of the Study:

  • To investigate the anti-cancer potential of novel tubulin-targeting agents (SPIKET and COBRA compounds) and protein tyrosine kinase inhibitors.
  • To evaluate the effects of these compounds on cancer cell viability, microtubule organization, and apoptosis.

Main Methods:

  • Treatment of human cancer cell lines (breast cancer, brain tumor, leukemia, lymphoma) with SPIKET, COBRA, EGFR inhibitors (WHI-P97, LFM-A12), and BTK inhibitors (LFM-A13).

Related Experiment Videos

  • Assessment of tubulin polymerization, microtubule organization, cytotoxicity, invasiveness, and apoptosis induction.
  • In vitro kinase inhibition assays for specific tyrosine kinases (JAK3, JAK1, JAK2, SYK, BTK, LYN, IRK).

    • Main Results:

    • SPIKET compound SPIKET-P caused tubulin depolymerization and potent cytotoxicity at nanomolar concentrations.
    • COBRA-1 inhibited tubulin polymerization, disrupted microtubule organization, and induced apoptosis in cancer cells.
    • EGFR inhibitors WHI-P97 and LFM-A12 inhibited invasiveness and induced apoptosis in EGFR-positive breast cancer cells.
    • WHI-P131 selectively inhibited JAK3 kinase activity.
    • LFM-A13 inhibited BTK and enhanced chemotherapy-induced apoptosis in leukemia cells.

    Conclusions:

    • SPIKET and COBRA compounds represent a new class of anti-cancer agents targeting tubulin.
    • EGFR and JAK/BTK kinase inhibitors demonstrate efficacy against various cancer types, offering potential therapeutic strategies.
    • These compounds show promise in disrupting cancer cell proliferation and survival, warranting further investigation.